3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Venous Thromboembolism
15
Venous Thrombosis
11
Pulmonary Embolism
10
Neoplasms
9
Thrombosis
4
Thromboembolism
4
Pancreatic Neoplasms
4
Lung Neoplasms
4
Multiple Myeloma
3
Neoplasm Metastasis
2
Lymphoma
2
Hemorrhage
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Uterine Cervical Neoplasms
1
Thrombophilia
1
Thrombocytopenia
1
Thrombocythemia, Essential
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Precancerous Conditions
1
Ovarian Neoplasms
1
Obesity
1
Neoplasms, Plasma Cell
1
Interventions
Irinotecan
6
Gemcitabine
5
130-nm albumin-bound paclitaxel
5
Oxaliplatin
4
Fluorouracil
4
Capecitabine
4
Bevacizumab
4
Albumin-Bound Paclitaxel
4
napabucasin
3
Ocoxin
3
Leucovorin
3
pembrolizumab
2
Sorafenib
2
Paclitaxel
2
Nivolumab
2
Cyclophosphamide
2
Cetuximab
2
Bupivacaine
2
Aspirin
2
Ascorbic Acid
2
trifluridine tipiracil drug combination
1
trametinib
1
pralsetinib
1
penpulimab
1
ozanimod
1
linifanib
1
hetrombopag
1
halofantrine
1
guadecitabine
1
golotimod
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Digestive System Diseases
×
Dalteparin
×
Clear all
NCT06153394
2024-04-23
PRIORITY
Western University, Canada
Phase 3
Not yet recruiting
50 enrolled